
    
      Comparison of ARIXTRAâ„¢ in lower LImb Superficial Thrombophlebitis with placebo (CALISTO). An
      International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group,
      Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for
      the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the
      Lower Limbs to prevent Thromboembolic Complications
    
  